Loading...
•
Dec 31, 2025
ImmunityBio Q4 2025 Earnings Report
ImmunityBio reported strong Q4 2025 revenue growth driven by ANKTIVA sales while net losses modestly increased year over year.
Key Takeaways
ImmunityBio generated $38285000 in total revenue in Q4 2025, primarily from ANKTIVA product sales, as commercialization accelerated. Net loss attributable to common stockholders was $61944000, reflecting continued investment in R&D and commercialization activities.
Q4 total revenue increased to $38285000 from $7552000 year over year.
Net product revenue reached $38272000 compared to $7206000 in Q4 2024.
Net loss attributable to common stockholders was $61944000.
R&D expenses rose significantly due to manufacturing scale-up and a $14000000 fixed asset write-off.
Revenue by Segment
Forward Guidance
The company plans continued global commercialization expansion and multiple regulatory submissions in 2026 while advancing over 30 clinical programs.
Positive Outlook
- Planned accelerated approval submissions for NSCLC in multiple jurisdictions in 2026.
- BLA filing targeted for Q4 2026 in BCG-naïve NMIBC.
- Expansion into 33 countries across four regulatory jurisdictions.
- Growing enrollment across multiple randomized clinical trials.
- Commercial infrastructure expansion in EU and Saudi Arabia.
Challenges Ahead
- Continued significant quarterly net losses.
- High R&D spending driven by clinical development and manufacturing scale-up.
- Revenue concentration in a single product.
- Ongoing reliance on external regulatory approvals.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...